- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Anti-CD20 Antibody Improves Lenalidomide Performance in CLL
From 20 months to upto 5 years, blocking CD20 significantly improved OS in CLL patients.
Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) lived twice as long when treated with lenalidomide (Revlimid) plus an anti-CD20 antibody compared with lenalidomide alone, a series of clinical trials showed.
Median overall survival increased from 20 months with lenalidomide alone to as much as much as 5 years with the addition of either of two monoclonal antibodies. As compared with lenalidomide alone, the combination improved response rate, time to treatment failure (TTF), and overall survival, Philip A. Thompson, MD, of the University of Texas MD Anderson Cancer Center in Houston, reported here at the European Hematology Association meeting.
"We observed similar results with lenalidomide and either ofatumumab (Arzerra) or rituximab (Rituxan)," said Thompson. "A subgroup of patients has highly durable remissions, even after cessation of treatment. Our focus for the future is on combining lenalidomide with more potent CD20 monoclonal antibodies and combining lenalidomide and a CD20 monoclonal antibody with other novel therapies.
Read the report here: http://bit.ly/1kSIKDQ
Source: Medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
